Share Price:

APNASPENAspen Pharmacare Hldgs181410 (0.00%)

Aspen is in a closed period from 1st July 2024 until the publication of the FY2024 results on the JSE SENS platform to be released on the 3rd September 2024.

Aspen partners with PinkDrive to mobilise cancer screening

Aspen has contributed towards the funding of a new mobile cancer screening clinic for rural and peri-urban disadvantaged communities.

FY 2024 Results Presentation

View the online version and select download options

Aspen’s revenue increases 10% underpinned by a strong second half performance

Stephen Saad Aspen Group Chief Executiv

JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid Group financial results for the year ended 30 June 2024.

Aspen’s Mandela Day programme changes more than 910 000 lives over 14 years

Durban – JSE Limited listed Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded pharmaceutical company, is celebrating its 14th consecutive year of Group-wide participation in Mandela Day.   Stephen Saad, Aspen Group Chief Executive said, “ Aspen has a track record of improving access to healthcare to all patients but more particularly the… Continue reading Aspen’s Mandela Day programme changes more than 910 000 lives over 14 years

Aspen backs Donald Ramphadi to bring home the gold in upcoming mobility impaired tennis championships

Donald Ramphadi and Stavros Nicolaou at the handover of his high performance wheelchair

Johannesburg, South Africa – Aspen Pharmacare Holdings Limited (“Aspen”), a global multinational specialty pharmaceutical company, has presented a state-of-the-art high performance wheelchair to South African wheelchair tennis star Donald Ramphadi.   Ramphadi, a French-open double quads champion and a prominent figure in wheelchair tennis, reached his maiden Grand Slam final at the Australian Open Wheelchair… Continue reading Aspen backs Donald Ramphadi to bring home the gold in upcoming mobility impaired tennis championships

Aspen announces additional pharmaceutical donations for Ukranian patients

(l-r): Ambassador and Plenipotentiary of Ukraine to South Africa H.E Liubov Abravitova; Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade; Former President of Ukraine H.E Viktor Yushchenko; Former first Lady Mrs Kateryna Yushchenko.

  Johannesburg, South Africa – Aspen Pharmacare, Africa’s largest pharmaceutical company, has announced continued humanitarian support to Ukraine, confirming further donations of critical care products to treat hospitalized patients who have been impacted by the ongoing conflict in that country.   Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade, said, “Aspen is highly sensitised to… Continue reading Aspen announces additional pharmaceutical donations for Ukranian patients

Aspen building momentum with revenue up 10% to R21,1 billion

Stephen Saad, Aspen Group Chief Executive

Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion

Aspen concludes two significant agreements with Sandoz for China and Europe

Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned subsidiary incorporated in Mauritius, has concluded two interdependent agreements with Sandoz AG (“Sandoz”) concerning the acquisition of Sandoz’s Chinese business and the disposal to Sandoz of four anaesthetic products in… Continue reading Aspen concludes two significant agreements with Sandoz for China and Europe

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.